Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
Although recent clinical trials targeting amyloid-β in Alzheimer’s disease have shown promising results, there is increasing evidence suggesting that understanding alternative disease pathways that interact with amyloid-β metabolism and amyloid pathology might be important to halt the clinical deterioration. In particular, there is evidence supporting a critical role of astroglial activation and astrocytosis in Alzheimer’s disease. However, so far, no studies have assessed whether astrocytosis is independently related to either amyloid-β or tau pathology in vivo. To address this question, we determined the levels of the astrocytic marker GFAP in plasma and CSF of 217 amyloid-β-negative cognitively unimpaired individuals, 71 amyloid-β-positive cognitively unimpaired individuals, 78 amyloid-β-positive cognitively impaired individuals, 63 amyloid-β-negative cognitively impaired individuals and 75 patients with a non-Alzheimer’s disease neurodegenerative disorder from the Swedish BioFINDER-2 study. Participants underwent longitudinal amyloid-β (18F-flutemetamol) and tau (18F-RO948) PET as well as cognitive testing. We found that plasma GFAP concentration was significantly increased in all amyloid-β-positive groups compared with participants without amyloid-β pathology (P < 0.01). In addition, there were significant associations between plasma GFAP with higher amyloid-β-PET signal in all amyloid-β-positive groups, but also in cognitively normal individuals with normal amyloid-β values (P < 0.001), which remained significant after controlling for tau-PET signal. Furthermore, plasma GFAP could predict amyloid-β-PET positivity with an area under the curve of 0.76, which was greater than the performance achieved by CSF GFAP (0.69) and other glial markers (CSF YKL-40: 0.64, soluble TREM2: 0.71). Although correlations were also observed between tau-PET and plasma GFAP, these were no longer significant after controlling for amyloid-β-PET. In contrast to plasma GFAP, CSF GFAP concentration was significantly increased in non-Alzheimer’s disease patients compared to other groups (P < 0.05) and correlated with amyloid-β-PET only in amyloid-β-positive cognitively impaired individuals (P = 0.005). Finally, plasma GFAP was associated with both longitudinal amyloid-β-PET and cognitive decline, and mediated the effect of amyloid-β-PET on tau-PET burden, suggesting that astrocytosis secondary to amyloid-β aggregation might promote tau accumulation. Altogether, these findings indicate that plasma GFAP is an early marker associated with brain amyloid-β pathology but not tau aggregation, even in cognitively normal individuals with a normal amyloid-β status. This suggests that plasma GFAP should be incorporated in current hypothetical models of Alzheimer’s disease pathogenesis and be used as a non-invasive and accessible tool to detect early astrocytosis secondary to amyloid-β pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, blood measures of p-tau181, p-tau217, p-tau231, glial fibrillary acid protein (GFAP), neurofilament light (NfL) and Aβ42/40 have been shown to change in preclinical AD and can discriminate this state from CU individuals with non-AD pathological changes1,3,6–13.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased GFAP, associated with astrogliosis, is a hallmark of and linked to pathological processes in Alzheimer’s disease, particularly amyloid build-up, and neuroinflammation [27].”
From Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer’s disease (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For GFAP we observed more pronounced group differences in blood than in CSF, as has also been observed by other groups [33, 75].”
In the citing paper
“Elevated levels of GFAP in plasma and serum are associated with the degree and rate of neurodegeneration, Aβ positivity and cognitive decline in individuals with AD [27, 28].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“There is increasing evidence suggesting that the pathogenesis of Alzheimer’s disease is not restricted to amyloid-b plaques and tau tangles but also includes strong interactions with immunological mechanisms.(1) In line with this, astrocyte reactivity or astrocytosis is a well-known pathological process that is common…”
BackgroundMethodJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 5×
“Plasma and CSF samples were collected in the morning during the same visit, with participants non-fasting.(40) Blood was collected in six EDTA-plasma tubes and centrifuged (2000g, + 4 C for 10 min).”
MethodInfluentialSelf-citationSynergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798
Self-citationTREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735 · cited 1×
“TREM2 variants seem to cause loss of function of TREM2 and reduce the ability of microglia to respond to toxic metabolites and clear them from the brain.(21) Although initial studies examining”
BackgroundSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citation
Research works printed but not linked: 1
- Palmqvist, 2019, Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease, EMBO Mol Med, 11, e11170, 10.15252/emmm.201911170 · DOI · Paper page
Cited by
Items 201–300 of 660
Serrano‐Pozo, A., Escott‐Price, V., Grinberg, L. T., Pascoal, T. A., Suárez‐Calvet, M., Dubois, B., & Sperling, R. A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00198-4 · Cited by 21
Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
Toniolo, S., Zhao, S., Scholcz, A., Amein, B., Ganse‐Dumrath, A., Heslegrave, A., Thompson, S., Manohar, S., Zetterberg, H., & Husain, M. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12590 · Cited by 21
Self-citationKoivumäki, M., Ekblad, L. L., Lantero‐Rodriguez, J., Ashton, N. J., Karikari, T. K., Helin, S., Parkkola, R. K., Lötjönen, J. M. P., Zetterberg, H., Blennow, K., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01477-w · Cited by 21
Self-citation[18F]-D3FSP β-amyloid PET imaging in older adults and alzheimer’s disease
Li, A., Zhao, R., Zhang, M., Sun, P., Cai, Y. Q., Zhu, L., Kung, H. F., Han, Y., Wang, X., & Guo, T. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06835-2 · Cited by 21
Navigating the Alzheimer’s Biomarker Landscape: A Comprehensive Analysis of Fluid-Based Diagnostics
Abiad, E. E., Al-Kuwari, A., Al-Aani, U., Jaidah, Y. A., & Châari, A. (2024) · Cells · doi:10.3390/cells13221901 · Cited by 21
Janelidze, S., Collij, L. E., Mattsson, N., Antill, A., Laymon, C. M., Lott, I. T., Rosas, H. D., Minhas, D. S., Luo, W., Zaman, S. H., et al. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00158-9 · Cited by 20
Self-citationZhao, D., Wang, J., Zhu, Y., Zhang, H., Ni, C., Zhao, Z., Dai, J., He, R., Liu, G.-Z., Gan, C., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00510-8 · Cited by 21
Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Aβ
Matafora, V., Gorb, A., Yang, F., Noble, W. J., Bachi, A., Perez‐Nievas, B. G., & Jiménez-Sánchez, M. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15875 · Cited by 20
Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
Mizutani, Y., Ohdake, R., Tatebe, H., Higashi, A., Shima, S., Ueda, A., Ito, M., Tokuda, T., & Watanabe, H. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11875-z · Cited by 20
Huang, Z., Haile, K., Gedefaw, L., Lau, B. W.-M., Jin, L. N., Yip, S. P., & Huang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115738 · Cited by 20
Symptoms and conventional treatments of Alzheimer's disease
Chorawala, M. R., Shah, A. C., Pandya, A. J., Kothari, N. R., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00009-1 · Cited by 21
Padrela, B. E., Mahroo, A., Tee, M., Sneve, M. H., Moyaert, P., Geier, O. M., Kuijer, J. P. A., Beun, S., Nordhøy, W., Zhu, Y. D., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-081635 · Cited by 20
Martínez‐Dubarbie, F., Guerra-Ruiz, A. R., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Infante, J., Pozueta‐Cantudo, A., García‐Martínez, M., Corrales‐Pardo, A., Bravo, M., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.152 · Cited by 20
Huang, K., Hsiao, I., Huang, C., Huang, C., Chang, H., Huang, S., Lin, K., Ma, M.-C., Huang, C., & Chang, C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14297 · Cited by 20
Hermann, P., Villar‐Piqué, A., Schmitz, M., Schmidt, C., Varges, D., Goebel, S., Bunck, T., Lindemann, H., Bogner, C., Santana, I. J., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00955-9 · Cited by 20
Natale, G., Kritikos, M., Kuan, P. F., Carr, M. A., Yang, X., Yang, Y., Kotov, R., Bromet, E. J., Clouston, S., & Luft, B. J. (2023) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2023.100631 · Cited by 20
Atlas of proteomic signatures of brain structure and its links to brain disorders
Ren, P., Hou, X., Li, Z., You, J., Li, Y., Zhang, W., Gong, W., Zhang, B., Wu, B., Wang, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60185-7 · Cited by 19
Kjærgaard, D., Nielsen, T. R., Stomrud, E., Palmqvist, S., Bali, D., Dolado, A. O., Janelidze, S., Hansson, O., Waldemar, G., & Simonsen, A. H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70315 · Cited by 19
Self-citationMedial temporal lobe gray matter microstructure in preclinical Alzheimer's disease
Brown, C., Das, S. R., Xie, L., Nasrallah, I. M., Detre, J. A., Chen‐Plotkin, A. S., Shaw, L. M. J., McMillan, C. T., Yushkevich, P. A., & Wolk, D. A. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13832 · Cited by 19
Bermudez, C. L., Syrjanen, J. A., Stricker, N. H., Algeciras‐Schimnich, A., Kouri, N., Kremers, W. K., Petersen, R. C., Jack, C. R., Knopman, D. S., Dickson, D. W., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100224 · Cited by 18
Mastrangelo, A., Vacchiano, V., Zenesini, C., Ruggeri, E., Baiardi, S., Cherici, A., Avoni, P., Polischi, B., Santoro, F., Capellari, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813976 · Cited by 18
Wang, X., Zhang, X., Liu, J., Zhang, J., Liu, C., Cui, Y., Song, Q., Hou, Y., Wang, Y., Zhang, Q., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01440-9 · Cited by 18
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Wicker, A., Shriram, J., Decourt, B., & Sabbagh, M. N. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00664-z · Cited by 18
Higher plasma soluble TREM2 correlates with reduced cerebral tau accumulation in Alzheimer’s disease
Lan, G., Li, A., González‐Ortiz, F., Lv, J., Ran, W., Cai, Y. Q., Sun, P., Liu, L., Yang, J., Zhang, L., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02976-4 · Cited by 18
Self-citationShrestha, S., Zhu, X., Griswold, M. E., Palta, P., Sullivan, K., Chen, H., Schneider, A. L. C., Moghekar, A., Grove, M. L., Thyagarajan, B., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213706 · Cited by 18
Prediction of longitudinal synaptic loss in Alzheimer's disease using tau PET and plasma biomarkers
Wang, J., Huang, Q., Chen, X., You, Z., He, K., Mao, X., Huang, Y. H., Franzmeier, N., Schöll, M., Guo, T., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70333 · Cited by 17
Machine learning-assisted optimization of dietary intervention against dementia risk
Chen, S., Chen, H., You, J., Chen, S.-D., Fu, Y., Zhang, W., Huang, L., Feng, J., Gao, X., Cheng, W., et al. (2025) · Nature Human Behaviour · doi:10.1038/s41562-025-02255-w · Cited by 17
Buonocore, J., Fratto, E., Arcuri, F., Vescio, B., Calomino, C., Talarico, M., Cristiani, C. M., Quattrone, A., & Quattrone, A. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13498-y · Cited by 17
Kisioglu, B., Önal, E., Karabulut, D., Onbaşılar, İ., & Akyol, A. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4520 · Cited by 17
Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease
Bellaver, B., Povala, G., Ferreira, P. C. L., Bauer‐Negrini, G., Lussier, F. Z., Leffa, D. T., Ferrari‐Souza, J. P., Rodrigues, M. S., Amaral, L., Oliveira, M. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70209 · Cited by 18
Self-citationXu, X., Mei, B., Yang, Y., Li, J., Weng, J., Yang, Y., Zhu, Q., Zhang, H., & Liu, X. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.109315 · Cited by 17
Mellingen, R. M., Myrmel, L. S., Rasinger, J. D., Lie, K. K., Bernhard, A., Madsen, L., & Nøstbakken, O. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012242 · Cited by 17
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 16
Recent advances in Alzheimer’s disease: From molecular mechanisms to therapeutic strategies
Rudman, M. D., Ulrich, J. D., & Holtzman, D. M. (2026) · Cell · doi:10.1016/j.cell.2026.06.006 · Cited by 18
Blutbasierte Biomarker zur Optimierung der Früh- und Differentialdiagnostik der Alzheimer-Demenz
Hansen, N., Rauter, C. M., & Wiltfang, J. (2022) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1839-6237 · Cited by 16
Thaker, A. A., McConnell, B. V., Rogers, D., Carlson, N. E., Coughlan, C. M., Jensen, A. M., Lopez‐Paniagua, D., Holden, S. K., Pressman, P., Pelak, V. S., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.06.026 · Cited by 16
Lorenzini, L., Zanella, L., Sannia, M., Baldassarro, V. A., Moretti, M., Cescatti, M., Quadalti, C., Baldi, S., Bartolucci, G., Gloria, L. D., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01471-2 · Cited by 16
Yu, X., Shi, R., Zhou, X., Zhang, M., Cai, Y., Jiang, J., & Han, Y. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14084 · Cited by 16
Kang, Y., Feng, Z., Zhang, Q., Liu, M., Li, Y., Yang, H., Zheng, L., Cheng, C., Zhou, W., Lou, D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14443 · Cited by 16
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease
Abbas, S., Ferreira, P. C. L., Bellaver, B., Povala, G., Rohden, F., Aguzzoli, C. S., Zalzale, H., Ferrari‐Souza, J. P., Leffa, D. T., Lussier, F. Z., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100205 · Cited by 16
Self-citationSuárez‐Calvet, M., Ruiz, C. A., Alcolea, D. A., Mendióroz, M., Balasa, M., Morenas‐Rodríguez, E., Puig‐Pijoan, A., Sánchez‐Juan, P., Villarejo‐Galende, A., & Sánchez‐Valle, R. (2025) · Neurología (English Edition) · doi:10.1016/j.nrleng.2025.07.004 · Cited by 16
Göschel, L., Dell’Orco, A., Fillmer, A., Aydın, S., Ittermann, B., Riemann, L. T., Lehmann, S., Cano, S., Melin, J., Pendrill, L., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14318 · Cited by 15
Self-citationChang, Y. Z., Liu, J., Xu, X., Sun, S., Zhang, J., Zhang, X., Lu, G., Xiao, S., Cao, Y., Wu, R., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07016-x · Cited by 15
Egroo, M. V., Beckers, E., Ashton, N. J., Blennow, K., Zetterberg, H., & Jacobs, H. I. L. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01653-y · Cited by 15
Self-citationInflammation biomarkers and Alzheimer's disease: A pilot study using NULISAseq
Molfetta, G. D., Pola, I., Tan, K., Isaacson, R., Blennow, K., Ashton, N. J., Benedet, A. L., & Zetterberg, H. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70079 · Cited by 15
Self-citationAxonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
Svenningsson, A. L., Stomrud, E., Palmqvist, S., Hansson, O., & Ossenkoppele, R. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01081-w · Cited by 15
Self-citationWarpechowski, M., Warpechowski, J. J., Kulczyńska‐Przybik, A., & Mroczko, B. (2022) · Medical Science Monitor · doi:10.12659/msm.938826 · Cited by 15
Association of APOE ε4/ε4 with fluid biomarkers in patients from the PUMCH dementia cohort
Shang, L., Dong, L., Huang, X., Wang, T., Mao, C., Li, J., Wang, J., Liu, C., & Gao, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1119070 · Cited by 15
Boerwinkle, A. H., Wisch, J. K., Handen, B. L., Head, E., Mapstone, M., Rafii, M. S., O'Bryant, S. E., Krinsky‐McHale, S. J., Lai, F., Rosas, H. D., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14359 · Cited by 14
Suchy‐Dicey, A. M., Longstreth, W. T., Rhoads, K., Umans, J. G., Buchwald, D., Grabowski, T. J., Blennow, K., Reiman, E. M., & Zetterberg, H. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13664 · Cited by 14
Self-citationChanges in Astroglial Water Flow in the Pre-amyloid Phase of the STZ Model of AD Dementia
Gayger-Dias, V., Menezes, L., Silva, V.-F. D., Stiborski, A., Silva, A. C. R., Sobottka, T. M., Quines-Silva, V. C., Souto, B. P., Bobermin, L. D., Quincozes‐Santos, A., et al. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04144-6 · Cited by 14
Biofluid biomarkers for Alzheimer’s disease: past, present, and future
An, C., Cai, H., Ren, Z., Fu, X., Quan, S., & Jia, L. (2024) · Medical Review · doi:10.1515/mr-2023-0071 · Cited by 14
Ikanga, J. N., Jean, K. R., Medina, P., Patel, S. S., Schwinne, M., Epenge, E., Gikelekele, G., Tshengele, N., Kavugho, I., Mampunza, S. M. M., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1477047 · Cited by 14
Self-citationZhu, P., Ji, W., Li, D., Wang, F., Sun, T., Yang, H., Chen, S., Zhang, W., Jin, Y., & Duan, G. (2024) · Journal of Virology · doi:10.1128/jvi.01514-24 · Cited by 14
Cacciaglia, R., Falcón, C., Sánchez‐Benavides, G., Brugulat‐Serrat, A., Alomà, M. M., Suárez‐Calvet, M., Molinuevo, J. L., Fauria, K., Minguillón, C., Kollmorgen, G., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14415 · Cited by 14
Self-citationMir, P. A., Kumar, N. G., Bhutia, G. T., Chaudhary, P., Kaur, G., & Gupta, S. K. (2026) · GeroScience · doi:10.1007/s11357-025-02062-1 · Cited by 14
Raza, A., Xie, W., Kim, K., Dronamraju, V., Williams, J. L., Vince, R., & More, S. S. (2022) · Antioxidants · doi:10.3390/antiox11061075 · Cited by 14
Zou, Y., Li, L., Guan, L., Ma, C., Yu, S., Ma, X., Mao, C., Gao, J., & Qiu, L. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1196272 · Cited by 14
Yuan, D., Huang, B., Gu, M., Qin, B., Su, Z., Dai, K., Peng, F., & Jiang, Y. (2023) · European Neurology · doi:10.1159/000533397 · Cited by 14
Diverse signaling mechanisms and heterogeneity of astrocyte reactivity in Alzheimer's disease
Qin, H., Zhou, L., Haque, F. T., Martín-Jiménez, C., Trang, A., Benveniste, E. N., & Wang, Q. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16002 · Cited by 14
Calluy, E., Beaudart, C., Alokail, M. S., Al‐Daghri, N. M., Bruyère, O., Reginster, J., Cavalier, E., & Ladang, A. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-0194 · Cited by 14
In Vivo Assessment of Astrocyte Reactivity in Patients with Progressive Supranuclear Palsy
Hirata, K., Matsuoka, K., Tagai, K., Endo, H., Tatebe, H., Ono, M., Kokubo, N., Kataoka, Y., Oyama, A., Shinotoh, H., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26962 · Cited by 13
Katsipis, G., Tzekaki, E., Andreadou, E. G., Mouzakidis, C., Baldimtsi, E. N., Karathanasi, E. M., Hassandra, M., Galanis, E., Hatzigeorgiadis, A., Goudas, M., et al. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104085 · Cited by 11
Multidimensional MRI reveals cortical astrogliosis linked to dementia in Alzheimer’s disease
Barsoum, S., Latimer, C. S., Nolan, A., Barrett, A., Chang, K., Troncoso, J. C., Keene, C. D., & Benjamini, D. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf245 · Cited by 13
Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort
Dresse, M. T., Ferreira, P. C. L., Prasadan, A., Diaz, J. L., Zeng, X., Bellaver, B., Povala, G., Villemagne, V. L., Kamboh, M. I., Cohen, A. D., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01803-w · Cited by 13
Epigenetic clocks and longitudinal plasma biomarkers of Alzheimer's disease
Zhang, B., McEvoy, L. K., Nguyen, S., Espeland, M. A., Rapp, S. R., Horvath, S., Lu, A. T.-H., LaCroix, A. Z., Nievergelt, C. M., Maihofer, A. X., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70983 · Cited by 13
Luarte, A., Nardocci, G., Chakraborty, A., Bátiz, L. F., Pino‐Lagos, K., & Wyneken, Ú. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106833 · Cited by 14
Milos, T., Vuić, B., Balic, N., Farkaš, V., Erjavec, G. N., Štrac, D. Š., Perković, M. N., & Pivac, N. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2400683 · Cited by 12
Suárez‐Calvet, M., Ruiz, C. A., Alcolea, D. A., Mendióroz, M., Balasa, M., Morenas‐Rodríguez, E., Puig‐Pijoan, A., Sánchez‐Juan, P., Villarejo‐Galende, A., & Sánchez‐Valle, R. (2024) · Neurología · doi:10.1016/j.nrl.2024.08.002 · Cited by 12
Gaubert, S., Garcés, P., Hipp, J. F., Bruña, R., López, M. E., Maestú, F., Vaghari, D., Henson, R. N., Paquet, C., & Engemann, D. A. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105659 · Cited by 12
Braudeau, J., Souchet, B., & Streel, E. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2025.100107 · Cited by 12
Kim, J. K., Anwar, M., Gupta, A., Thyagarajan, B., Hu, P., Faul, J. D., Weir, D. R., Langa, K. M., Lee, J., Dey, S., et al. (2025) · American Journal of Epidemiology · doi:10.1093/aje/kwaf179 · Cited by 12
Ghanbarian, E., Qian, T., Khorsand, B., Zheng, L., Sajjadi, S. A., Grill, J. D., Rabin, L. A., Lipton, R. B., Sperling, R. A., & Ezzati, A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70948 · Cited by 12
Guha, D., Misra, V., Chettimada, S., Yin, J., & Gabuzda, D. H. (2023) · Viruses · doi:10.3390/v16010072 · Cited by 12
Single-Cell RNA-seq reveals transcriptomic modulation of Alzheimer’s disease by activated protein C
Fatmi, M. K., Wang, H., Slotabec, L. A., Wen, C., Seale, B. C., Zhao, B., & Li, J. (2024) · Aging · doi:10.18632/aging.205624 · Cited by 12
Investigation of the Circular Transcriptome in Alzheimer’s Disease Brain
Gao, Y., Xu, S.-M., Cheng, Y., Takenaka, K., Lindner, G., & Janitz, M. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02236-0 · Cited by 12
Blood-based biomarkers of Alzheimer’s disease—A guideline for clinical use
Shi, J., Ou, Q., & Chen, X. (2024) · Medicine Plus · doi:10.1016/j.medp.2024.100057 · Cited by 11
Ma, W., Frigon, É., Maranzano, J., Zeighami, Y., & Dadar, M. (2024) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2024.1477973 · Cited by 11
Heritability of Alzheimer's disease plasma biomarkers: A nuclear twin family design
Rousset, R. Z., den Braber, A., Verberk, I. M. W., Boonkamp, L., Wilson, D. H., Ligthart, L., Teunissen, C. E., & de Geus, E. J. C. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14269 · Cited by 11
Self-citationPlasma Biomarkers in the Distinction of Alzheimer’s Disease and Frontotemporal Dementia
Gómez‐Tortosa, E., Agüero, P., Ruiz-González, A., Wagner, S., Téllez, R., Mahíllo, I., Ruiz-Calvo, A., Sainz, M. J., Nystrom, A. L., del Ser, T., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031231 · Cited by 12
Neuropathologic correlates of distinct plasma biomarker profiles in community-living older adults
Yu, L., Du, L., Wang, T., Barnes, L. L., Dage, J. L., Russ, K. A., Foroud, T., Bennett, D. A., Schneider, J. A., & Boyle, P. A. (2025) · Brain · doi:10.1093/brain/awaf211 · Cited by 12
Method comparison of plasma and CSF GFAP immunoassays across multiple platforms
Arslan, B., Rembeza, E., Rasch, S., Andréasson, U., Blennow, K., Zetterberg, H., & Kvartsberg, H. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0667 · Cited by 11
Self-citationUm, Y. H., Wynveen, P., Holland, M., Bhatt, K. P., Vucetic, Z., Engel, B., Carlson, C. M., Becker, A., Meier, I. B., Narayan, V. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70942 · Cited by 11
Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 years
den Braber, A., Verberk, I. M. W., Tomassen, J., den Dulk, B., Stoops, E., Dage, J. L., Collij, L. E., Barkhof, F., Willemsen, G. A. H. M., Nivard, M. G., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcad024 · Cited by 11
Self-citationXu, Y., Jiang, H., Zhu, B., Cao, M., Feng, T., Sun, Z., Du, G., & Zhao, Z. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14238 · Cited by 11
Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer’s Disease
Bhalala, O. G., Watson, R., & Yassi, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021231 · Cited by 11
Novel Development and Prospects in Pathogenesis, Diagnosis, and Therapy of Alzheimer’s Disease
Teng, Z. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230130 · Cited by 11
Biofluid biomarkers for Alzheimer’s disease
Wang, S., Xie, S., Zheng, Q., Zhang, Z., Wang, T., & Zhang, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380237 · Cited by 11
Altomare, D., Libri, I., Alberici, A., Rivolta, J., Padovani, A., Ashton, N. J., Zetterberg, H., Blennow, K., & Borroni, B. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01474-z · Cited by 11
Self-citationClinical significance of plasma candidate biomarkers of Alzheimer’s Disease
Lewczuk, P., Łukaszewicz‐Zając, M., Kornhuber, J., & Mroczko, B. (2024) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.100675 · Cited by 11
Behof, W. J., Whitmore, C. A., Haynes, J. R., Rosenberg, A. J., Tantawy, M. N., Peterson, T. E., Harrison, F. E., Beelman, R. B., Wijesinghe, P., Matsubara, J. A., et al. (2022) · FEBS Letters · doi:10.1002/1873-3468.14303 · Cited by 11
ATN blood biomarkers are related to digital cognitive assessment in type 1 diabetes
Fonseca, L. M., Beeri, M. S., Hawks, Z., Jung, L., Cleveland, M. J., Delgado, N., Bulger, J., Grinspoon, E. A., Janess, K., Sliwinski, M. J., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70029 · Cited by 10
Plasma biomarker trajectories: Impact of AD genetic risk and clinical progression
Pettigrew, C. A., Soldan, A., Wang, J., Hohman, T. J., Dumitrescu, L. C., Albert, M., Blennow, K., Bittner, T., Moghekar, A., & The BIOCARD Study Team (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70081 · Cited by 10
Self-citationBekena, S., Singh, R. K., Zhu, Y., Cruchaga, C., Arnold, S. E., Ances, B. M., & Babulal, G. M. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251378675 · Cited by 10
Halbgebauer, S., Fazeli, B., Klose, V., Nagel, G., Rosenbohm, A., Rothenbacher, D., Bachhuber, F., Jesse, S., Otto, M., Landwehrmeyer, G. B., et al. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf120 · Cited by 10
Mao, X., Wang, Y., Luan, Y., Wang, Y., Wang, J., Dai, W., Guan, Y., Huang, Q., Gunn, R. N., Ossenkoppele, R., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00906-0 · Cited by 10
Combined multi-omics and brain pathology reveal novel biomarkers for alzheimer’s disease
Zhao, Q., Gou, C., Luo, G., Dai, S., Wang, D., Zhang, S., Wang, F., Xu, H. M., Han, Y., & Wang, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-21983-7 · Cited by 10
Maschio, C., Moreno, Ó., Wang, J., Maheshwari, U., Keller, A., Konietzko, U., Razansky, D., Nordberg, A. K., Rominger, A., Höck, C., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01916-2 · Cited by 10
Fesharaki‐Zadeh, A. (2023) · Biomedicines · doi:10.3390/biomedicines11123158 · Cited by 10
Kandeil, M. A., Mohammed, E. T., Ibrahim, M. A., Radi, R. A., Fouad, A. G., Abdel‐Razik, A. H., Khalıl, F., & Sabry, D. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05241-5 · Cited by 9
Metadata
- Authors
- Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden
- Amsterdam Neuroscience (NL)
- Sahlgrenska University Hospital (SE)
- King's College London (GB)
- Corresponding author
- Pereira, Joana B
- Hansson, Oskar
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-02
- Volume
- 144
- Issue
- 11
- Pages
- 3505-3516
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC8677538
- OpenAlex
- W3182927843
- Cited by
- 598
- References
- 61
- Citations by year
- 2026: 148 · 2025: 140 · 2024: 141 · 2023: 92 · 2022: 66 · 2021: 10
- FWCI
- 48.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Swedish Research Council (2016–00906, 2018–02052, #2018–02201, #2017–00915, #2018–02532)
- Knut and Alice Wallenberg foundation (2017–0383)
- Marianne and Marcus Wallenberg foundation (2015.0125)
- Strategic Research Area MultiPark
- Swedish Alzheimer Foundation (AF-939932, #AF-742881)
- Swedish Brain Foundation (FO2019-0326)
- The Parkinson foundation of Sweden (1280/20)
- Skåne University Hospital Foundation (2020-O000028)
- Regionalt Forskningsstöd (2020–0314)
- Swedish federal government (2018-Projekt0279)
- The Center for Medical Innovation (#20200695)
- Karolinska Institute
- Alzheimer Drug Discovery Foundation (#RDAPB-201809–2016615)
- Hjärnfonden, Sweden (#FO2017-0243)
- ALF (#ALFGBG-715986)
- European Union Joint Program for Neurodegenerative Disorders (JPND2019-466–236)
- European Research Council (#681712)
- Swedish State Support for Clinical Research (#ALFGBG-720931)
- UK Dementia Research Institute
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, tau pathology, astrocyte activation, astroglial activation, biomarkers, cerebrospinal fluid biomarkers, amyloid PET, tau PET, 18F-flutemetamol, cognitive impairment
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.